Rare kidney cancer hides from immune system, making standard treatments ineffective.
Researchers studying a rare kidney cancer have found that it behaves very differently from other kidney tumors. This cancer, called chromophobe renal cell carcinoma, doesn’t attract the same immune response that doctors typically rely on to help fight the disease. In most kidney cancers, certain immune cells, especially T-cells, try to attack the tumor, even if they don’t always succeed. With this rare kind, those T-cells barely show up at all—or, when they do, they don’t react. That makes it hard for the body to even recognize that there’s something wrong.
A recent report from a group of cancer scientists looked more closely at what’s happening inside these tumors. By breaking down the makeup of the tumor cells and comparing them to normal kidney cells, the researchers found that this type of cancer seems to come from a specific kind of kidney cell. From there, the rare kidney cancer seems to turn off certain parts of the immune system that would normally step in. This quiet escape from detection helps explain why current treatments don’t do much for people with this condition.
Most existing treatments were built to work on more common kidney cancers. Those usually have a lot of T-cells around the tumor, though those cells may be tired out or blocked. In that case, treatments known as immune checkpoint inhibitors are used to try to wake the cells up and get them fighting again. But with this rare cancer, there aren’t enough T-cells to begin with, and the few that are there seem unaffected by the drugs. This makes the usual approach nearly useless.
To get a better picture, the team used advanced tools to study cells one by one. They used computer programs to sort through the genetic activity in the tumors, comparing it to normal kidney tissue. They could see which genes were turned on or off in the cancer, which gave them clues about how the tumor forms and hides. They also looked at immune cells inside the tumor and found that they were either missing or not working the way they should. This kind of mapping gives scientists a clearer idea of where to focus next.
Several major cancer centers worked together on this project, including Yale, Brigham and Women’s Hospital, Dana-Farber, and MD Anderson. It was a large effort, pulling in experts from across the U.S. and Canada. Still, the number of samples was fairly small, which means more studies are needed to confirm these early results.
One key point from the research is that the way this cancer avoids the immune system is not just a weaker version of what happens in more common kidney cancers. It’s a totally different trick. That means scientists can’t just tweak old treatments—they’ll need to build new ones from the ground up. Some possible ideas include developing ways to bring more immune cells into the tumor or waking up cells that are already there but staying silent.
For now, doctors are limited in what they can offer people diagnosed with this rare cancer. The disease doesn’t respond well to the treatments that work for other types, and it’s harder to study because it doesn’t show up often. But this recent work offers a starting point for future therapies that match the cancer’s behavior more closely.
This study, while early, points toward new paths for treating a type of kidney cancer that doesn’t play by the usual rules. Scientists now have a better idea of why this cancer is so hard to fight—and what needs to change to give patients better options in the future.
Join the conversation!